Project Grant R50CA288588
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $194K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This Project Grant award, totaling $102,984, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The award supports research by The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, to perform spatio-temporal analyses of the entire brain-metastatic arc, from single-cell interaction with the blood-brain-barrier to fully developed brain metastases. The research will...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The Trustees of the University of Pennsylvania to support the development and implementation of NCI-sponsored clinical trials for rare cancers. The $122,610 award, which began in August 2025, aims to: Assist junior and mid-career oncology faculty in developing investigator-initiated studies, and Develop a program within the National Clinical Trials Network (NCTN) to design...
- The National Cancer Institute (NCI) awarded a $361,695 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Oklahoma Health Sciences Center (OUHSC) for the period of September 1, 2025 to August 31, 2029. The grant aims to: 1) Leverage novel mHealth applications to boost enrollment in NCI-sponsored clinical trials, 2) Promote representative clinical trial enrollment from the local catchment area population, 3) Expand Veteran access to NCI trials, and 4)...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,006,599 to Weill Medical College of Cornell University from September 1, 2025 through August 31, 2029 to expand NCI-sponsored clinical research in hematologic malignancies to the Brooklyn and Queens regions of New York City. The funding supports the integration of interdisciplinary research at the Meyer Cancer Center to address cancer prevention, treatment, and educational outreach...
- This federal Project Grant award, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research focused on understanding the relationship between inflammatory signaling in the leptomeninges and the growth of leptomeningeal metastatic tumors. The $730,398 award to the Sloan-Kettering Institute for Cancer Research, located in New York, will leverage mouse models and single-cell RNA sequencing to investigate how cancer cell signals induce...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $197,518 to The Children's Hospital of Philadelphia (CHOP) to address barriers to conducting clinical trials for patients with rare tumors. The awardee, who serves as Chair of the Children's Oncology Group (COG) Rare Tumor Disease Committee and Study Chair for three COG clinical trials, will use the funding to: Expand the availability of rare tumor clinical trials within COG,...
- The National Cancer Institute (NCI) awarded a Project Grant of $375,025 to the University of Maryland, Baltimore under the Cancer Treatment Research federal grant program (CFDA 93.395). The grant supports Dr. Mark Mishra, who plays a critical role in the University of Maryland Greenebaum Comprehensive Cancer Center's clinical trials program and NCI-funded research. The key goals of the award are to: 1) Expand access to NCI-sponsored clinical trials at new network sites; 2) Foster partnerships to...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $1,625,853 Project Grant to New York University (NYU) on December 13, 2024. The grant will support NYU's research to map and characterize the role of 3D "hubs" - regulatory DNA elements that interact with multiple loci - in the context of T-cell leukemia (T-ALL), early T-cell progenitor leukemia (ETP-ALL), and T-cell lymphoma. The project aims to better define how these 3D chromatin structures are rewired...
- This $292,028 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms by which oncogene amplification leads to genome instability and the development of therapy-resistant cancer clones. The research will be conducted by the Sloan-Kettering Institute for Cancer Research in New York and is scheduled to run from August 1, 2025 to July 31, 2030. Using single-cell genomic sequencing techniques, the project aims...
- This federal Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) provides $153,348 to The Trustees of Columbia University in the City of New York to conduct in-depth mechanistic and in vivo functional studies of single-nucleotide variants (SNVs) that modulate T cell activity for cancer immunotherapies. The research aims to define the mechanisms by which certain PIK3CD SNVs enhance T cell activity and evaluate their impact in murine...